Incorporating a personalized mRNA vaccine, designed to match an individual’s tumor genetics, into standard immunotherapy substantially boosts survival rates and reduces the recurrence of high-risk skin cancers in patients who have had these malignancies removed.
Global trials that could revolutionize cancer treatment and save countless lives are being led by scientists from Edith Cowan University (ECU).
Clinical Professor Adnan Khattak from ECU’s Centre for Precision Health recently unveiled the newest findings from these trials at the 2023 American Society of Oncology (ASCO) congress in Chicago. The ASCO congress, attracting more than 45,000 participants, is the largest cancer treatment conference worldwide.
After 18 months, cancer-free survival among patients who received the vaccine and the immunotherapy treatment was 78.6 percent, compared to 62.2 percent of those who only received the immunotherapy.
Two years after treatment, only 22.4 percent of patients who had received the vaccine/immunotherapy combination had either died or seen a recurrence of the disease, which rose to 40 percent for the immunotherapy-only group.
Overall, after an average of two years, those who received the vaccine saw a 44 percent lower risk of death or melanoma returning to the same area of the body, and a 65 percent reduction in the risk of death or the cancer returning in a different area of the body.
Crucially, there was no significant increase in rates of adverse side effects.
Professor Khattak said the trial began as a way of trying to address the shortcomings of current treatments.
“The current standard of care is immunotherapy using an antibody known as pembrolizumab,” he said.
“There are two main issues: first, despite having active immunotherapy for stage three melanoma, about half of the patients will relapse at five years.
“And secondly, it’s a very crude approach: currently if I treat 10 new high-risk melanoma patients, I give them the same drug; it’s not rocket science that it’s going to work for some but not others, and some may see side effects and others may not.
“This is the biggest trial to show treatment improves with an individualized approach — and I think research into personal cancer vaccines is going to increase dramatically after this positive study.”
Getting to know you — and your disease
Though vaccines are typically associated with disease prevention, in this instance the mRNA vaccine is used to treat people who have already been diagnosed with melanoma.
Samples of tissue are taken and analyzed to identify neoantigens, proteins that form on cancer cells, and which are unique to an individual’s tumor.
Up to 34 neoantigens may be identified, which are then added to an mRNA molecule and added to a vaccine.
The result is a personalized cancer treatment, with the neoantigens most likely to develop an immune response to help the patient’s body fight cancer.
Professor Khattak said it appeared to be more effective after an extended period of time and required multiple doses.
“In this study, the survival rate between the two groups is the same after 40 weeks, so early relapses happen for both,” he said.
“Some patients have fairly resistant tumors that aren’t going to respond to either of the treatments.
“But after the first 40 weeks, by then the patients have had two or three vaccine doses and the anti-tumor effect really kicks in.
“We see quite a significant proportion of patients relapsing after they finish pembrolizumab, whereas we’re not seeing such late relapses in patients who have done the double treatment because in addition to pembrolizumab, the effect of the vaccine kicks in with a much stronger anti-tumor immune response.”
Next steps
Professor Khattak will soon lead a new global trial of the treatment,
His clinic in Perth, Western Australia recruited the most participants of any site in the world.
“I would like to thank all my patients who took part in this research at a difficult point in their life,” Professor Khattak said.
The new trial will include more participants, some with earlier stages of melanoma.
“Stage two and stage three patients combined constitute quite a significant proportion of patients who could be potentially cured, rather than waiting for them to develop metastatic or advanced disease where most of them will not be curable,” he said.
If successful, the trial could be the starting point of a new approach to cancer treatment, beyond just melanoma.
“This is going to be the stepping stone for a number of trials,” Professor Khattak said.
“Because now they have expanded it into lung cancer, kidney cancers, and also into gastrointestinal cancers.
“This has the potential of becoming a new standard of care moving forward.”
Meeting: 2023 American Society of Oncology
Those looking for details on the trial can contact One Clinical Research.
The research was funded by Moderna, Merck Sharp and Dohme.
News
New study shows risk factors for dementia – virus causes deposits in the brain
Research into the causes of Alzheimer's is not yet complete. Now a new study shows that head trauma can activate herpes viruses and promote the disease. Frankfurt am Main – As a neurodegenerative disease, [...]
Are Machines Truly Thinking? Modern AI Systems Have Finally Achieved Turing’s Vision
Modern AI systems have fulfilled Turing’s vision of machines that learn and converse like humans, but challenges remain. A new paper highlights concerns about energy consumption and societal inequality while calling for more robust [...]
The Surprising Link Between Smell, Sound, and Emotions
New research reveals how smell and hearing interact in the brain to drive social behavior, using mouse maternal instincts as a model. Imagine you’re at a dinner party, but you can’t smell the food [...]
Brain cells age at different rates
As our body ages, not only joints, bones and muscles wear out, but also our nervous system. Nerve cells die, are no longer fully replaced, and the brain shrinks. "Aging is the most important risk factor [...]
Long COVID Breakthrough: Spike Proteins Persist in Brain for Years
Researchers have discovered that the SARS-CoV-2 spike protein persists in the brain and skull bone marrow for years after infection, potentially leading to chronic inflammation and neurodegenerative diseases. Researchers from Helmholtz Munich and Ludwig-Maximilians-Universität (LMU) have [...]
Water-Resistant Paper Could Revolutionize Packaging and Replace Plastic
A groundbreaking study showcases the creation of sustainable hydrophobic paper, enhanced by cellulose nanofibres and peptides, presenting a biodegradable alternative to petroleum-based materials, with potential uses in packaging and biomedical devices. Researchers aimed to [...]
NIH Scientists Discover Game-Changing Antibodies Against Malaria
Novel antibodies have the potential to pave the way for the next generation of malaria interventions. Researchers at the National Institutes of Health (NIH) have identified a novel class of antibodies that target a previously unexplored region [...]
Surprising Discovery: What If Some Cancer Genes Are Actually Protecting You?
A surprising discovery reveals that a gene previously thought to accelerate esophageal cancer actually helps protect against it initially. This pivotal study could lead to better prediction and prevention strategies tailored to individual genetic [...]
The Cancer Test That Exposes What Conventional Scans Miss
Researchers at UCLA have unveiled startling findings using PSMA-PET imaging that reveal nearly half of patients diagnosed with high-risk prostate cancer might actually have metastases missed by traditional imaging methods. This revelation could profoundly affect future [...]
Pupil size in sleep reveals how memories are processed
Cornell University researchers have found that the pupil is key to understanding how, and when, the brain forms strong, long-lasting memories. By studying mice equipped with brain electrodes and tiny eye-tracking cameras, the researchers [...]
Stanford’s Vaccine Breakthrough Boosts Flu Protection Like Never Before
Stanford Medicine researchers have developed a new method for influenza vaccination that encourages a robust immune response to all four common flu subtypes, potentially increasing the vaccine’s efficacy. In laboratory tests using human tonsil [...]
Water’s Worst Nightmare: The Rise of Superhydrophobic Materials
New materials with near-perfect water repellency offer potential for self-cleaning surfaces in cars and buildings. Scientists from Karlsruhe Institute of Technology (KIT) and the Indian Institute of Technology Guwahati (IITG) have developed a surface [...]
Japanese dentists test drug to help people with missing teeth regrow new ones
Japanese dentists are testing a groundbreaking drug that could enable people with missing teeth to grow new ones, reducing the need for dentures and implants, AFP recently reported. Katsu Takahashi, head of oral surgery at [...]
An AI system has reached human level on a test for ‘general intelligence’
A new artificial intelligence (AI) model has just achieved human-level results on a test designed to measure "general intelligence." On December 20, OpenAI's o3 system scored 85% on the ARC-AGI benchmark, well above the previous AI best [...]
According to Researchers, Your Breathing Patterns Could Hold the Key to Better Memory
Breathing synchronizes brain waves that support memory consolidation. A new study from Northwestern Medicine reports that, much like a conductor harmonizes various instruments in an orchestra to create a symphony, breathing synchronizes hippocampal brain waves to [...]
The Hidden Culprit Behind Alzheimer’s Revealed: Microglia Under the Microscope
Researchers at the CUNY Graduate Center have made a groundbreaking discovery in Alzheimer’s disease research, identifying a critical link between cellular stress in the brain and disease progression. Their study focuses on microglia, the brain’s immune [...]
